Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Performance of gene expression-based single sample predictors for assessment of clinicopathological subgroups and molecular subtypes in cancers: a case comparison study in non-small cell lung cancer.

Cirenajwis H, Lauss M, Planck M, Vallon-Christersson J, Staaf J.

Brief Bioinform. 2019 Feb 4. doi: 10.1093/bib/bbz008. [Epub ahead of print]

PMID:
30721923
2.

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.

Helgadottir H, Ghiorzo P, van Doorn R, Puig S, Levin M, Kefford R, Lauss M, Queirolo P, Pastorino L, Kapiteijn E, Potrony M, Carrera C, Olsson H, Höiom V, Jönsson G.

J Med Genet. 2018 Oct 5. pii: jmedgenet-2018-105610. doi: 10.1136/jmedgenet-2018-105610. [Epub ahead of print]

3.

Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing.

Artomov M, Stratigos AJ, Kim I, Kumar R, Lauss M, Reddy BY, Miao B, Daniela Robles-Espinoza C, Sankar A, Njauw CN, Shannon K, Gragoudas ES, Marie Lane A, Iyer V, Newton-Bishop JA, Timothy Bishop D, Holland EA, Mann GJ, Singh T, Daly MJ, Tsao H.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx083.

4.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T, Kvist A, Ringnér M, Svane IM, Jönsson G.

Nat Commun. 2017 Nov 23;8(1):1738. doi: 10.1038/s41467-017-01460-0.

5.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

6.

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.

Cirenajwis H, Lauss M, Ekedahl H, Törngren T, Kvist A, Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C, Harbst K, Hayward NK, Jönsson G.

Mol Oncol. 2017 Apr;11(4):438-451. doi: 10.1002/1878-0261.12050. Epub 2017 Mar 24.

7.

Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities.

Lauss M, Nsengimana J, Staaf J, Newton-Bishop J, Jönsson G.

J Invest Dermatol. 2016 Dec;136(12):2502-2505. doi: 10.1016/j.jid.2016.05.119. Epub 2016 Jun 23. No abstract available.

8.

High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.

Ekedahl H, Lauss M, Olsson H, Griewank KG, Schadendorf D, Ingvar C, Jönsson G.

Pigment Cell Melanoma Res. 2016 Sep;29(5):598-600. doi: 10.1111/pcmr.12500. Epub 2016 Aug 1. No abstract available.

PMID:
27301352
9.

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.

Harbst K, Lauss M, Cirenajwis H, Isaksson K, Rosengren F, Törngren T, Kvist A, Johansson MC, Vallon-Christersson J, Baldetorp B, Borg Å, Olsson H, Ingvar C, Carneiro A, Jönsson G.

Cancer Res. 2016 Aug 15;76(16):4765-74. doi: 10.1158/0008-5472.CAN-15-3476. Epub 2016 May 23.

10.

An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.

Holm K, Staaf J, Lauss M, Aine M, Lindgren D, Bendahl PO, Vallon-Christersson J, Barkardottir RB, Höglund M, Borg Å, Jönsson G, Ringnér M.

Breast Cancer Res. 2016 Feb 29;18(1):27. doi: 10.1186/s13058-016-0685-5.

11.

Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.

Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jönsson G, Rha SY, Tsao H.

J Invest Dermatol. 2016 May;136(5):1002-1011. doi: 10.1016/j.jid.2016.01.024. Epub 2016 Feb 15.

12.

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes.

Lauss M, Ringnér M, Karlsson A, Harbst K, Busch C, Geisler J, Lønning PE, Staaf J, Jönsson G.

BMC Med Genomics. 2015 Nov 6;8:73. doi: 10.1186/s12920-015-0147-4.

13.

Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes.

Johansson I, Lauss M, Holm K, Staaf J, Nilsson C, Fjällskog ML, Ringnér M, Hedenfalk I.

Mol Oncol. 2015 Oct;9(8):1565-79. doi: 10.1016/j.molonc.2015.04.013. Epub 2015 May 8.

14.

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren T, Kvist A, Fredlund E, Bendahl PO, Jirström K, Lundgren L, Howlin J, Borg Å, Gruvberger-Saal SK, Saal LH, Nielsen K, Ringnér M, Tsao H, Olsson H, Ingvar C, Staaf J, Jönsson G.

Oncotarget. 2015 May 20;6(14):12297-309.

15.

A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S, Kollberg P, Eriksson P, Aine M, Månsson W, Fernö M, Liedberg F, Höglund M.

Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.

PMID:
25770486
16.

Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours.

Howlin J, Cirenajwis H, Lettiero B, Staaf J, Lauss M, Saal L, Borg Å, Gruvberger-Saal S, Jönsson G.

PeerJ. 2015 Feb 26;3:e788. doi: 10.7717/peerj.788. eCollection 2015.

17.

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G.

J Invest Dermatol. 2015 Jul;135(7):1820-1828. doi: 10.1038/jid.2015.61. Epub 2015 Feb 23.

18.

Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.

Karlsson A, Jönsson M, Lauss M, Brunnström H, Jönsson P, Borg Å, Jönsson G, Ringnér M, Planck M, Staaf J.

Clin Cancer Res. 2014 Dec 1;20(23):6127-40. doi: 10.1158/1078-0432.CCR-14-1087. Epub 2014 Oct 2.

19.

The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.

Jewell R, Elliott F, Laye J, Nsengimana J, Davies J, Walker C, Conway C, Mitra A, Harland M, Cook MG, Boon A, Storr S, Safuan S, Martin SG, Jirström K, Olsson H, Ingvar C, Lauss M, Bishop T, Jönsson G, Newton-Bishop J.

Pigment Cell Melanoma Res. 2015 Jan;28(1):94-104. doi: 10.1111/pcmr.12315. Epub 2014 Oct 1.

20.

Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history.

Karlsson A, Ringnér M, Lauss M, Botling J, Micke P, Planck M, Staaf J.

Clin Cancer Res. 2014 Sep 15;20(18):4912-24. doi: 10.1158/1078-0432.CCR-14-0246. Epub 2014 Jul 18.

21.

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Staaf J, Harbst K, Lauss M, Ringnér M, Måsbäck A, Howlin J, Jirström K, Harland M, Zebary A, Palmer JM, Ingvar C, Olsson H, Newton-Bishop J, Hansson J, Hayward N, Gruis N, Jönsson G.

J Invest Dermatol. 2014 Dec;134(12):3000-3003. doi: 10.1038/jid.2014.272. Epub 2014 Jul 7. No abstract available.

22.

Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.

Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, Månsson W, Fernö M, Leandersson K, Lindgren D, Liedberg F, Höglund M.

Urol Oncol. 2014 Aug;32(6):791-7. doi: 10.1016/j.urolonc.2014.02.007. Epub 2014 Apr 29.

23.

Molecular and genetic diversity in the metastatic process of melanoma.

Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Törngren T, Kvist A, Nodin B, Olsson E, Häkkinen J, Jirström K, Staaf J, Lundgren L, Olsson H, Ingvar C, Gruvberger-Saal SK, Saal LH, Jönsson G.

J Pathol. 2014 May;233(1):39-50. doi: 10.1002/path.4318. Epub 2014 Jan 27.

24.

Monitoring of technical variation in quantitative high-throughput datasets.

Lauss M, Visne I, Kriegner A, Ringnér M, Jönsson G, Höglund M.

Cancer Inform. 2013 Sep 23;12:193-201. doi: 10.4137/CIN.S12862. eCollection 2013.

25.

Toward a molecular pathologic classification of urothelial carcinoma.

Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D, Fernö M, Liedberg F, Höglund M.

Am J Pathol. 2013 Sep;183(3):681-91. doi: 10.1016/j.ajpath.2013.05.013. Epub 2013 Jul 1.

26.

Efficient arsenic metabolism--the AS3MT haplotype is associated with DNA methylation and expression of multiple genes around AS3MT.

Engström KS, Hossain MB, Lauss M, Ahmed S, Raqib R, Vahter M, Broberg K.

PLoS One. 2013;8(1):e53732. doi: 10.1371/journal.pone.0053732. Epub 2013 Jan 14.

27.

DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status.

Lauss M, Aine M, Sjödahl G, Veerla S, Patschan O, Gudjonsson S, Chebil G, Lövgren K, Fernö M, Månsson W, Liedberg F, Ringnér M, Lindgren D, Höglund M.

Epigenetics. 2012 Aug;7(8):858-67. doi: 10.4161/epi.20837. Epub 2012 Jun 18.

28.

The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading.

Liedberg F, Lauss M, Patschan O, Aine M, Chebil G, Cwikiel M, Engilbertsson H, Gudjonsson S, Kollberg P, Sjödahl G, Månsson W, Lindgren D, Höglund M; Lund Bladder Cancer Group.

Eur Urol. 2012 Oct;62(4):620-3. Epub 2012 Jun 5. No abstract available.

PMID:
22698575
29.

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson W, Fernö M, Höglund M.

PLoS One. 2012;7(6):e38863. doi: 10.1371/journal.pone.0038863. Epub 2012 Jun 7.

30.

Molecular profiling reveals low- and high-grade forms of primary melanoma.

Harbst K, Staaf J, Lauss M, Karlsson A, Måsbäck A, Johansson I, Bendahl PO, Vallon-Christersson J, Törngren T, Ekedahl H, Geisler J, Höglund M, Ringnér M, Lundgren L, Jirström K, Olsson H, Ingvar C, Borg Å, Tsao H, Jönsson G.

Clin Cancer Res. 2012 Aug 1;18(15):4026-36. doi: 10.1158/1078-0432.CCR-12-0343. Epub 2012 Jun 6. Erratum in: Clin Cancer Res. 2012 Oct 15;18(20):5829. Höglund, Markus [corrected to Höglund, Mattias]; Ringnér, Mattias [corrected to Ringnér, Markus].

31.

A molecular taxonomy for urothelial carcinoma.

Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M.

Clin Cancer Res. 2012 Jun 15;18(12):3377-86. doi: 10.1158/1078-0432.CCR-12-0077-T. Epub 2012 May 2.

32.

Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.

Johansson I, Nilsson C, Berglund P, Lauss M, Ringnér M, Olsson H, Luts L, Sim E, Thorstensson S, Fjällskog ML, Hedenfalk I.

Breast Cancer Res. 2012 Feb 14;14(1):R31.

33.

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Sjödahl G, Lauss M, Gudjonsson S, Liedberg F, Halldén C, Chebil G, Månsson W, Höglund M, Lindgren D.

PLoS One. 2011 Apr 14;6(4):e18583. doi: 10.1371/journal.pone.0018583.

34.

Robust assignment of cancer subtypes from expression data using a uni-variate gene expression average as classifier.

Lauss M, Frigyesi A, Ryden T, Höglund M.

BMC Cancer. 2010 Oct 6;10:532. doi: 10.1186/1471-2407-10-532.

35.

Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study.

Lauss M, Ringnér M, Höglund M.

Clin Cancer Res. 2010 Sep 1;16(17):4421-33. doi: 10.1158/1078-0432.CCR-10-0606. Epub 2010 Aug 24.

36.

RGG: a general GUI Framework for R scripts.

Visne I, Dilaveroglu E, Vierlinger K, Lauss M, Yildiz A, Weinhaeusel A, Noehammer C, Leisch F, Kriegner A.

BMC Bioinformatics. 2009 Mar 2;10:74. doi: 10.1186/1471-2105-10-74.

37.

The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.

Weinhaeusel A, Scheuba C, Lauss M, Kriegner A, Kaserer K, Vierlinger K, Haas OA, Niederle B.

Thyroid. 2008 Dec;18(12):1269-76. doi: 10.1089/thy.2008.0139.

PMID:
18976163
38.

MethCancerDB--aberrant DNA methylation in human cancer.

Lauss M, Visne I, Weinhaeusel A, Vierlinger K, Noehammer C, Kriegner A.

Br J Cancer. 2008 Feb 26;98(4):816-7. doi: 10.1038/sj.bjc.6604219. Epub 2008 Feb 5.

39.

Comparison of RNA amplification techniques meeting the demands for the expression profiling of clinical cancer samples.

Lauss M, Vierlinger K, Weinhaeusel A, Szameit S, Kaserer K, Noehammer C.

Virchows Arch. 2007 Dec;451(6):1019-29. Epub 2007 Oct 31.

PMID:
17972098
40.

Consensus genes of the literature to predict breast cancer recurrence.

Lauss M, Kriegner A, Vierlinger K, Visne I, Yildiz A, Dilaveroglu E, Noehammer C.

Breast Cancer Res Treat. 2008 Jul;110(2):235-44. Epub 2007 Sep 26.

PMID:
17899371
41.

Characterization of the drugged human genome.

Lauss M, Kriegner A, Vierlinger K, Noehammer C.

Pharmacogenomics. 2007 Aug;8(8):1063-73. Review.

PMID:
17716238
42.

Single inner cell masses yield embryonic stem cell lines differing in lifr expression and their developmental potential.

Lauss M, Stary M, Tischler J, Egger G, Puz S, Bader-Allmer A, Seiser C, Weitzer G.

Biochem Biophys Res Commun. 2005 Jun 17;331(4):1577-86.

PMID:
15883053

Supplemental Content

Support Center